Analysts expect Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) to report earnings per share of ($0.86) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Trillium Therapeutics’ earnings, with estimates ranging from ($1.07) to ($0.75). Trillium Therapeutics reported earnings per share of ($0.78) during the same quarter last year, which would suggest a negative year over year growth rate of 10.3%. The company is expected to report its next earnings results on Thursday, November 9th.

On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($3.91) per share for the current financial year, with EPS estimates ranging from ($4.78) to ($2.89). For the next year, analysts expect that the company will post earnings of ($3.17) per share, with EPS estimates ranging from ($3.88) to ($2.72). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Trillium Therapeutics.

Several analysts have recently weighed in on TRIL shares. Zacks Investment Research downgraded Trillium Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. HC Wainwright started coverage on Trillium Therapeutics in a research report on Monday, July 17th. They set a “buy” rating and a $7.00 target price for the company. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $18.00 target price on shares of Trillium Therapeutics in a research report on Friday, June 9th. Finally, Cowen and Company reiterated a “buy” rating on shares of Trillium Therapeutics in a research report on Wednesday, July 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $14.95.

Trillium Therapeutics (TRIL) opened at 5.00 on Thursday. Trillium Therapeutics has a 12 month low of $4.15 and a 12 month high of $17.70. The firm’s 50-day moving average is $4.65 and its 200-day moving average is $5.27. The stock’s market capitalization is $53.97 million.

TRADEMARK VIOLATION NOTICE: “-$0.86 Earnings Per Share Expected for Trillium Therapeutics Inc. (TRIL) This Quarter” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/28/0-86-earnings-per-share-expected-for-trillium-therapeutics-inc-tril-this-quarter.html.

Several large investors have recently added to or reduced their stakes in TRIL. NEA Management Company LLC bought a new stake in shares of Trillium Therapeutics during the second quarter worth $4,619,000. AWM Investment Company Inc. bought a new stake in shares of Trillium Therapeutics during the second quarter worth $4,415,000. Janus Henderson Group PLC bought a new stake in shares of Trillium Therapeutics during the second quarter worth $2,395,000. Tekla Capital Management LLC bought a new stake in shares of Trillium Therapeutics during the second quarter worth $1,980,000. Finally, Victory Capital Management Inc. lifted its position in shares of Trillium Therapeutics by 88.9% during the second quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 68,970 shares during the last quarter. Institutional investors and hedge funds own 47.97% of the company’s stock.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related stocks with our FREE daily email newsletter.